首页> 外文期刊>Bone marrow transplantation >Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact
【24h】

Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact

机译:同种异体造血干细胞移植后神经系统并发症:风险因素和影响

获取原文
获取原文并翻译 | 示例
       

摘要

Neurologic complications (NCs) may be a significant source of morbidity and mortality after hematopoietic cell transplantation (HCT). We performed a retrospective study of 263 consecutive patients undergoing allogeneic HCT for hematological malignancies to determine the incidence, risk factors and clinical impact of NCs in the first 5 years after HCT. We determined the incidence of central nervous system (CNS) infection, intracranial hemorrhage, ischemic stroke, metabolic encephalopathy, posterior reversal encephalopathy syndrome, seizure and peripheral neuropathy. In all, 50 patients experienced 63 NCs-37 early (= day + 100), 21 late (day + 101 to 2 years) and 5 very late (2 to 5 years). The 1- and 5-year cumulative incidences of all NCs were 15.6% and 19.2%, respectively, and of CNS complication (CNSC; all of the above complications except peripheral neuropathy) were 12.2 and 14.5%. Risk factors for CNSC were age (hazard ratio (HR) = 1.06 per year, P = 0.0034), development of acute GvHD grade III-IV (HR = 2.78, P=0.041), transfusion-dependent thrombocytopenia (HR = 3.07, P = 0.025) and delayed platelet engraftment ( 90th centile; HR = 2.77, P = 0.043). CNSCs negatively impacted progression-free survival (HR = 2.29, P = 0.0001), overall survival (HR = 2.63, P 0.0001) and non-relapse mortality (HR = 8.51, P 0.0001). NCs after HCT are associated with poor outcomes, and usually occur early after HCT.
机译:神经系统并发症(NCS)可能是造血细胞移植(HCT)后的发病率和死亡率的重要来源。我们对接受同种异体HCT的263名患者进行了回顾性研究,用于血液恶性肿瘤,以确定HCT后前5年中NCS的发病率,危险因素和临床影响。我们确定了中枢神经系统(CNS)感染的发病率,颅内出血,缺血性卒中,代谢脑病,后逆转脑病综合征,癫痫发作和周围神经病变。总而言之,50名患者经历了63个NCS-37早期(& = day + 100),21例(日+ 101至2年),5岁(2至5年)。所有NCS的1和5年累积发病率分别为15.6%和19.2%,以及CNS并发症(CNSC;外周神经病变外的所有上述并发症)为12.2和14.5%。 CNSC的危险因素是年龄(危险比(HR)= 1.06每年,P = 0.0034),急性GVHD级IV-II-IV的发育(HR = 2.78,P = 0.041),输血依赖性血小板减少症(HR = 3.07,P = 0.025)和延迟血小板植入(& 90厘厘; hr = 2.77,p = 0.043)。 CNSCs对无进展生存(HR = 2.29,P = 0.0001)产生负面影响(HR = 2.29,P = 0.0001),总存活(HR = 2.63,P <0.0001)和非复发死亡率(HR = 8.51,P <0.0001)。 HCT后NCS与差的结果相关,通常在HCT后早期发生。

著录项

  • 来源
    《Bone marrow transplantation》 |2018年第2期|共8页
  • 作者单位

    Walter &

    Eliza Hall Inst Med Res Immunol Div Parkville Vic Australia;

    Dana Farber Canc Inst Boston MA 02115 USA;

    Massachusetts Gen Hosp Canc Ctr Boston MA 02114 USA;

    Massachusetts Gen Hosp Canc Ctr Boston MA 02114 USA;

    Massachusetts Gen Hosp Canc Ctr Boston MA 02114 USA;

    Massachusetts Gen Hosp Canc Ctr Boston MA 02114 USA;

    Massachusetts Gen Hosp Canc Ctr Boston MA 02114 USA;

    Univ Virginia Canc Ctr Univ Virginia Hlth Syst Dept Med Stem Cell Transplant Program 1215 Lee;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号